Literature DB >> 22274775

Evidence-based review on the natural history of the epilepsies.

Dieter Schmidt1, Matti Sillanpää.   

Abstract

PURPOSE OF REVIEW: The present review discusses clinically important evidence for unstable remission/relapse patterns and for causes of premature mortality in patients with epilepsy. RECENT
FINDINGS: Although two of three patients become seizure-free with antiepileptic drugs (AEDs), as many as 20-40% of newly diagnosed patients with epilepsy become seizure-free without or with minimal AED treatment. Sadly, the proportion of those not becoming seizure-free despite treatment does not seem to have improved substantially over the past 50 years. There is emerging evidence that natural history of epilepsies is more complex than previously thought. Although two-thirds of patients follow stable patterns, that is, become seizure-free early and remain seizure-free (48%), or have refractory epilepsy all their life (19%), one in every three patients has an unstable course of epilepsy. Patients with an unstable course will either enter remission only after many years of having seizures (19%) or will relapse despite continued treatment (14%). Remote symptomatic epilepsy carries the highest risk of premature mortality. It remains unclear, however, why sudden unexplained death occurs more often in adults than in children and controversy exists whether entering remission prevents premature mortality.
SUMMARY: Studies of the natural history of newly diagnosed epilepsy show unexplained fluctuations of remission and relapse in as many as one in three patients and, sadly, no substantial improvement of epilepsy treatment in the past 50 years. The premature mortality of epilepsy is high and more work is needed to prevent it.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274775     DOI: 10.1097/WCO.0b013e3283507e73

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  20 in total

Review 1.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

Review 2.  Issues related to development of new antiseizure treatments.

Authors:  Karen S Wilcox; Tracy Dixon-Salazar; Graeme J Sills; Elinor Ben-Menachem; H Steve White; Roger J Porter; Marc A Dichter; Solomon L Moshé; Jeffrey L Noebels; Michael D Privitera; Michael A Rogawski
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

Review 3.  Issues related to development of antiepileptogenic therapies.

Authors:  Asla Pitkänen; Astrid Nehlig; Amy R Brooks-Kayal; F Edward Dudek; Daniel Friedman; Aristea S Galanopoulou; Frances E Jensen; Rafal M Kaminski; Jaideep Kapur; Henrik Klitgaard; Wolfgang Löscher; Istvan Mody; Dieter Schmidt
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

4.  Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs.

Authors:  Peter J West; Gerald W Saunders; Peggy Billingsley; Misty D Smith; H Steve White; Cameron S Metcalf; Karen S Wilcox
Journal:  Epilepsia       Date:  2018-10-17       Impact factor: 5.864

5.  Overexpressing wild-type γ2 subunits rescued the seizure phenotype in Gabrg2+/Q390X Dravet syndrome mice.

Authors:  Xuan Huang; Chengwen Zhou; Mengnan Tian; Jing-Qiong Kang; Wangzhen Shen; Kelienne Verdier; Aurea Pimenta; Robert L MacDonald
Journal:  Epilepsia       Date:  2017-06-06       Impact factor: 5.864

6.  [Chronic phosphoproteomic in temporal lobe epilepsy mouse models induced by kainic acid].

Authors:  Z M Sun; Q Chen; M H Li; W N Ma; X Y Zhao; Z Huang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-18

Review 7.  Pharmacoresistance and the role of surgery in difficult to treat epilepsy.

Authors:  Samuel Wiebe; Nathalie Jette
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

8.  A multi-dataset time-reversal approach to clinical trial placebo response and the relationship to natural variability in epilepsy.

Authors:  Daniel M Goldenholz; Alex Strashny; Mark Cook; Robert Moss; William H Theodore
Journal:  Seizure       Date:  2017-10-23       Impact factor: 3.184

Review 9.  Pharmacological and Therapeutic Approaches in the Treatment of Epilepsy.

Authors:  Shampa Ghosh; Jitendra Kumar Sinha; Tarab Khan; Kuramkote Shivanna Devaraju; Prabhakar Singh; Kumar Vaibhav; Pankaj Gaur
Journal:  Biomedicines       Date:  2021-04-25

Review 10.  MicroRNAs as regulators of brain function and targets for treatment of epilepsy.

Authors:  Gary P Brennan; David C Henshall
Journal:  Nat Rev Neurol       Date:  2020-06-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.